Fos-related antigen 1 (FOSL1) mRNA (FOSL1 mRNA)

Fos-related antigen 1 (FOSL1) mRNA is a critical therapeutic target in oncology, encoding a member of the AP-1 transcription factor family that regulates genes involved in cell proliferation, differentiation, and transformation (1.2.1, 1.3.2). In various aggressive malignancies, such as triple-negative breast cancer and KRAS-mutant lung adenocarcinoma, FOSL1 mRNA is frequently overexpressed and serves as a key driver of the epithelial-mesenchymal transition (EMT), metastasis, and chemoresistance (1.3.1, 1.3.3). By coordinating signaling from oncogenic pathways like Ras/ERK and TGF-beta, FOSL1 promotes an invasive cellular phenotype and metabolic reprogramming, including enhanced aerobic glycolysis (1.2.5, 1.3.3). Targeting FOSL1 mRNA directly using RNA interference (siRNA) or antisense oligonucleotides (ASOs) offers a strategy to downregulate the oncoprotein and inhibit its downstream transcriptional programs (1.4.1, 1.4.4). While no FOSL1-targeted therapies have reached clinical approval, preclinical studies have demonstrated that silencing FOSL1 mRNA can effectively reduce tumor growth and restore sensitivity to chemotherapy (1.1.2, 1.4.1). Challenges in targeting this molecule include ensuring efficient delivery to tumor tissues and minimizing potential off-target effects on normal physiological processes, such as bone and lipid metabolism, where FOSL1 also plays a role (1.3.2, 1.4.3).

Other names

FRA1FRA-1FOS-like 1FOS-like antigen 1AP-1 transcription factor subunit

RNA interference (siRNA) and antisense inhibition (ASO) targeting the FOSL1 transcript to prevent translation and induce mRNA degradation, thereby downregulating the FOSL1/FRA1 protein product.